Eledon's Tegoprubart Shows Promise in Phase 1b Kidney Transplant Trial with Superior Organ Function Preservation
核心洞察
Eledon Pharmaceuticals reported positive Phase 1b trial results for tegoprubart, an anti-CD40L (搜索) antibody, demonstrating successful prevention of kidney transplant rejection (搜索) in 11 participants with only one mild rejection case.
The treatment maintained aggregate mean estimated glomerular filtration rate above 70 mL/min/1.73m² after day 90, significantly higher than the typical low 50s range seen with standard tacrolimus therapy.
Tegoprubart showed a favorable safety profile without common tacrolimus-associated side effects including hyperglycemia (搜索), new onset diabetes (搜索), tremor, or cytomegalovirus infection (搜索).
Eledon Pharmaceuticals reported encouraging Phase 1b trial results for tegoprubart, an investigational anti-CD40L (搜索) antibody designed to prevent kidney transplant rejection (搜索) while preserving organ function. The data, presented at the American Society of Nephrology Kidney Week 2023 Annual Meeting, demonstrated that the novel immunosuppressive therapy successfully prevented rejection in kidney transplant recipients with a superior safety profile compared to current standard of care.
Trial Results Show Strong Efficacy Signal
The Phase 1b open-label study enrolled 11 participants who underwent kidney transplantation across Canada, Australia, and the United Kingdom. Results showed that tegoprubart effectively prevented transplant rejection, with only one participant experiencing a mild T-cell mediated rejection (Banff score 1a) on day 99. This patient was successfully treated and remained in the study, with no cases of graft loss or death reported.
"In this Phase 1b trial, patients treated with tegoprubart demonstrated robust improvements in eGFR with a strong safety profile," said Dr. John S. Gill, Professor of Medicine at the University of British Columbia and Principal Investigator of the study. "These results further support the promise of CD40L (搜索) costimulatory blockade in organ transplantation."
Superior Kidney Function Preservation
A key finding was the preservation of kidney function as measured by estimated glomerular filtration rate (eGFR). The aggregate mean eGFR remained above 70 mL/min/1.73m² at all reported time points after day 90, substantially higher than historical studies showing average eGFRs in the low 50 mL/min/1.73m² range during the first year after kidney transplant using standard of care treatments.
One participant completed the full study with an eGFR of 91 at one year (day 374) and has enrolled in a Phase 2 open-label extension study to evaluate long-term safety and efficacy.
Improved Safety Profile
Tegoprubart demonstrated a notably cleaner safety profile compared to tacrolimus, the current standard immunosuppressive therapy. Participants experienced no cases of hyperglycemia (搜索), new onset diabetes (搜索), tremor, or cytomegalovirus infection (搜索)—side effects commonly associated with tacrolimus treatment.
"We are excited to present updated safety and efficacy results from our ongoing Phase 1b trial which continue to support the potential of tegoprubart as a novel kidney transplant immunosuppressive therapy to prevent rejection and better preserve organ function without many of the side effects associated with tacrolimus," said David-Alexandre C. Gros, Chief Executive Officer of Eledon.
Treatment Protocol and Mechanism
Each participant received rabbit antithymocyte globulin (ATG) induction followed by a maintenance regimen consisting of tegoprubart, mycophenolate mofetil, and corticosteroids (搜索). The primary endpoint focused on safety, with secondary endpoints including pharmacokinetic characterization, incidence of biopsy-proven rejection, and eGFR measurements.
Tegoprubart is an anti-CD40L (搜索) antibody with high affinity for CD40 (搜索) Ligand, targeting the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation positions it as an attractive target for immunomodulatory intervention without lymphocyte depletion.
Phase 2 BESTOW Trial Advancement
Building on these Phase 1b results, Eledon initiated the Phase 2 BESTOW trial in September 2023. This multicenter, two-arm, active comparator study will enroll approximately 120 participants undergoing kidney transplantation in the United States and other countries to directly compare tegoprubart's safety, pharmacokinetics, and efficacy against tacrolimus.
The BESTOW trial's primary endpoint is designed to test the potential superiority of tegoprubart versus tacrolimus in post-kidney transplant function at 12 months as measured by eGFR. The company expects to complete enrollment by the end of 2024, with additional Phase 1b readouts anticipated in 2024.